A Healthcare Technology Company

Shaping the future of noninvasive diagnosis with artificial intelligence.

Uniquely Positioned among Noninvasive Technologies

A combination of broadly available biomarkers and neural network-based AI provides noninvasive diagnostic accuracy equivalent to biopsy​.

Fibronostics patent technology

Patented Technology

High Clinical Value

Fibronostics CE mark

CE mark

(Conformité Européenne)

Fibronostics patent technology

AI Technology-based

Ease of Use

Ease of Use

Complete Diagnostic Interrogation of the Liver

LIVERFASt™ helps determine the degree of fibrosis, activity & steatosis in the liver of NAFLD patients from early stage to late stage disease.

Fibronostics Screening


Risk stratification among large patient populations allows
for better management leading to cost reductions.

Fibronostics Diagnosis


Noninvasive disease detection means earlier diagnosis and
earlier intervention for better patient outcomes.

Fibronostics Monitoring


Regular surveillance with easily repeatable noninvasive
diagnostics enables optimized disease management.

Noninvasive testing for screening, diagnosing and monitoring.